|
Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product
|
Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product - in development as a treatment for several cancers - under a new contract signed by the two companies. Cellceutix said the deal was a major step forward to its goal of filing for approval to start clinical testing of the drug in the US. The firm said it would use the material for animal toxicology studies and phase I human trials.
Original article can be viewed here. |
Sitemap